Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$101.46+7.65 (+8.15%)
Close on Nov 18, 2026Market cap $8.95BP/E –Yield –
Spyre Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Spyre Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$208.94M. For fiscal 2025 it was -$169.25M. The highest annual figure on record is -$7.34M in fiscal 2014.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$169.25M | – |
| FY2024 | Dec 31, 2024 | -$157.41M | – |
| FY2023 | Dec 31, 2023 | -$99.91M | – |
| FY2022 | Dec 31, 2022 | -$80.14M | – |
| FY2021 | Dec 31, 2021 | -$53.72M | – |
| FY2020 | Dec 31, 2020 | -$75.78M | – |
| FY2019 | Dec 31, 2019 | -$65.69M | – |
| FY2018 | Dec 31, 2018 | -$32.19M | – |
| FY2017 | Dec 31, 2017 | -$24.62M | – |
| FY2016 | Dec 31, 2016 | -$18.84M | – |
| FY2015 | Dec 31, 2015 | -$10.98M | – |
| FY2014 | Dec 31, 2014 | -$7.34M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$69.88M | – |
| Q1 FY2026 | Mar 31, 2026 | -$57.37M | – |
| Q4 FY2025 | Dec 31, 2025 | -$44.58M | – |
| Q3 FY2025 | Sep 30, 2025 | -$37.12M | – |
| Q2 FY2025 | Jun 30, 2025 | -$46.56M | – |
| Q1 FY2025 | Mar 31, 2025 | -$40.99M | – |
| Q4 FY2024 | Dec 31, 2024 | -$37.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$29.42M | – |
| Q2 FY2024 | Jun 30, 2024 | -$62.25M | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.54M | – |
| Q4 FY2023 | Dec 31, 2023 | -$31.04M | – |
| Q3 FY2023 | Sep 30, 2023 | -$34.60M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.64M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.63M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.14M | – |
| Q3 FY2022 | Sep 30, 2022 | -$15.07M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.67M | -1092.9% |
| Q1 FY2022 | Mar 31, 2022 | -$26.26M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.00M | – |
| Q2 FY2021 | Jun 30, 2021 | $2.08M | – |
| Q1 FY2021 | Mar 31, 2021 | -$19.53M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.13M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.54M | – |
| Q2 FY2020 | Jun 30, 2020 | -$19.41M | – |
| Q1 FY2020 | Mar 31, 2020 | -$21.69M | – |
| Q4 FY2019 | Dec 31, 2019 | -$16.29M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.21M | – |
| Q2 FY2019 | Jun 30, 2019 | -$16.38M | – |
| Q1 FY2019 | Mar 31, 2019 | -$15.81M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.20M | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.50M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.04M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.45M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.87M | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.37M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.94M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.43M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.36M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.87M | – |
See a number that looks wrong?